-Invivoscribe se asocia con Complete Genomics para desarrollar y comercializar pruebas de biomarcadores para oncología e investigación del cáncer SAN DIEGO y SAN JOSÉ, California, 2 de junio de 2023 /PRNewswire/ — Invivoscribe y Complete Genomics han anunciado hoy que se han asociado para desarrollar y comercializar pruebas de biomarcadores en las plataformas NGS de Complete … Read more
SAN DIEGO y SAN JOSÉ, California, 2 de junio de 2023 /PRNewswire/ — Invivoscribe y Complete Genomics anunciaron hoy que habían celebrado un acuerdo para desarrollar y comercializar pruebas de biomarcadores en las plataformas NGS de Complete Genomics. El territorio es mundial, y el campo es oncología e investigación del cáncer. En virtud de los … Read more
Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina’s Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO, June 2, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term … Read more
An oral presentation titled “Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results” will be provided by Howard Safran, MD during the ASCO Developmental Therapeutics – Immunotherapy Session on June 4th. WALTHAM, Mass., June 2, 2023 /PRNewswire/ — Dragonfly Therapeutics, … Read more
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ — TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs for unmet medical needs, is currently seeking participants for a Phase 1 clinical trial … Read more
HONG KONG, June 1, 2023 /PRNewswire/ — Akeso Inc. (9926. HK, “Akeso”) announced today that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia (HeFH). Ebronucimab is jointly developed … Read more
SAN DIEGO, June 1, 2023 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th … Read more
SAN DIEGO, June 1, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat at the conference. … Read more
GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 8, 2023 Time: 9:00 – 9:25 a.m. Eastern Daylight Time (EDT) Location: New York, … Read more
-Dr. Robin Edwards y Dr. David Ferry se unen al equipo de liderazgo clínico de Dragonfly para ayudar a administrar su cartera clínica en crecimiento Seis fármacos desarrollados por Dragonfly se encuentran actualmente en la clínica. WALTHAM, Mass., 1 de junio de 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., anunció hoy que ha ampliado su equipo … Read more